CytomX Therapeutics (CTMX) Receivables - Net (2014 - 2026)

CytomX Therapeutics has reported Receivables - Net for 13 years, with the latest figure at $646000.0 in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Net fell 66.97% year-over-year to $646000.0; the trailing twelve-month figure through Mar 2026 stood at $646000.0 (down 66.97% YoY), and the FY2025 full-year result was $2.0 million, down 35.13% from the prior year.
• Receivables - Net for Q1 2026 stood at $646000.0, down from $2.0 million in the prior quarter.
• The five-year high for Receivables - Net was $36.0 million in Q4 2022, with the low at $646000.0 in Q1 2026.
• Historically, Receivables - Net has averaged $4.7 million across 5 years, with a median of $2.0 million in 2025.
• Annual changes were most pronounced in 2022 — Receivables - Net soared 4455.19% — and 2023, when it slumped 90.46%.
• CytomX Therapeutics' Receivables - Net stood at $36.0 million in 2022, then tumbled by 90.46% to $3.4 million in 2023, then retreated by 9.59% to $3.1 million in 2024, then slumped by 35.13% to $2.0 million in 2025, then plunged by 67.91% to $646000.0 in 2026.
• The last three Receivables - Net figures came in at $646000.0 (Q1 2026), $2.0 million (Q4 2025), and $1.6 million (Q3 2025), per Business Quant data.